Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ZÜRICH, Switzerland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics...
-
ZÜRICH, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
-
ZÜRICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by CDR-Life, please note that in the second paragraph of the release, the...
-
ZÜRICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
-
ZÜRICH, Switzerland, Dec. 13, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
-
ZÜRICH, Switzerland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
-
ZÜRICH, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
-
ZÜRICH, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., today announced that Boehringer Ingelheim has selected an antibody fragment-based therapeutic candidate for advancement to...